US seniors in Medicare "doughnut hole" cut back on drugs by 14%
This article was originally published in Scrip
Executive Summary
One of the most controversial aspects of the US Medicare prescription drug benefit is the annual limit on what the programme will pay for an individual patient's drug expenses, a measure designed to keep the overall cost of the programme within federally approved limits.